Approval · Notice of Compliance 11636 · 2010
RITUXAN: Notice of Compliance 11636
Issued July 29, 2010
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 11636
- Date
- July 29, 2010
- Company
- Hoffmann-La Roche LimitedMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition to the Rheumatoid Arthritis (RA) indication: Rituxan in combination with Methotrexate has been shown to reduce the rate of progression of joint damage as measured by x-ray
- Therapeutic class
- Antineoplastic
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RITUXAN | Not yet assigned | — |
Medicinal ingredients
- RITUXIMAB 10 MG per ML